Related Experiment Videos
Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy
Insights
Choosing the right hypertension medication is key. Factors like age, race, and drug effects influence treatment success for elevated systemic vascular resistance.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Essential hypertension is characterized by elevated systemic vascular resistance.
- This resistance can be influenced by sympathetic tone, the renin-angiotensin system, and vascular wall abnormalities.
Purpose of the Study:
- To compare the efficacy and effects of different antihypertensive agents.
- To identify factors influencing drug response in hypertension management.
Main Methods:
- Comparative analysis of antihypertensive drug classes.
- Consideration of patient demographics, pathophysiology, and drug mechanisms.
Main Results:
- Angiotensin-converting enzyme inhibitors may be more effective in younger patients, while calcium channel blockers might benefit elderly patients.
- Alpha-1 adrenergic blockers show efficacy across all age groups and are often more effective in Black patients.
- Alpha-1 blockers may improve lipid profiles, and calcium channel blockers can offer cardiac benefits.
Conclusions:
- Drug selection for hypertension requires consideration of patient-specific factors like age and race.
- Efficacy, side-effect profiles, and metabolic effects are crucial for initial antihypertensive therapy.
- Alpha-1 adrenergic blockers and calcium channel blockers present distinct advantages in specific patient populations.
Abstract:
The primary hemodynamic hallmark of essential hypertension is elevated systemic vascular resistance that may be affected by increased sympathetic tone, activation of the renin-angiotensin system, or structural and cellular abnormalities (e.g., those involving calcium) of the blood vessel wall. The aim of therapy, therefore, is to reduce vascular tone through the use of a specific blocker of neurohormonal mechanisms or a nonspecific vasodilator. These agents are not equally effective in all patients. In comparing these drugs, the following issues are important: pathophysiology, patient demography, mechanism of drug action, long-term efficacy, and metabolic effects. Several studies have suggested that there is a response to angiotensin converting enzyme inhibitors in young and middle-aged patients, whereas in elderly patients there may be more of a response to calcium channel blockers. Alpha 1-adrenergic blockers, however, appear to be effective in all age groups. Calcium channel blockers and alpha 1-adrenergic blockers generally are more effective in black patients than are angiotensin converting enzyme inhibitors. Neither of these agents adversely affects serum potassium, glucose, or plasma lipid levels. In fact, data suggest that alpha 1-adrenergic blockers may reduce low-density lipoprotein cholesterol and triglyceride levels and increase high-density lipoprotein cholesterol levels. Unlike alpha-adrenergic blockers and angiotensin converting enzyme inhibitors, calcium channel blockers may produce a negative inotropic effect and improved cardiac diastolic relaxation. In addition to all of these factors, it is important that the agent selected as initial antihypertensive therapy be efficacious, have a favorable side-effects profile, and have no adverse influences on other risk factors.